Lothian NHS Board

NHS Lothian Headquarters
Waverley Court
4 East Market Street
Edinburgh
EH8 8BG
www.nhslothian.scot

Date 28 July 2026
Your Ref
Our Ref 11636

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – MS PRESCRIBING

I write in response to your request for information in relation to MS Prescribing.

Question:

1. How many patients received treatment for any condition in the last six months with any of the following treatment regimens (November 2025 – April 2026)?
   - Ocrevus (ocrelizumab) IV (300mg/30ml)
   - Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
   - Kesimpta (ofatumumab)
   - Briumvi (ublituximab)
   - Mavenclad (cladribine)
   - Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
   - Natalizumab (Tysabri and Tyruko)

Answer:

November 2025 - April 2026	
Medication	**Patient Count**
Ocrevus (ocrelizumab) IV (300mg/30ml)	Information Unavailable
Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	Information Unavailable
Kesimpta (ofatumumab)	245
Briumvi (ublituximab)	Information Unavailable
Mavenclad (cladribine)	5<
Dimethyl Fumarate (Tecfidera)	5<
Dimethyl Fumarate (generic)	331
Natalizumab (Tysabri)	Information Unavailable
Natalizumab (Tyruko)	0

Question:

2. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in May 2025 to October 2025 AND November 2025-April 2026)

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

Answer:

Patients who received treatment in both periods: May 2025–October 2025 and November 2025–April 2026.	
Medication	**Patient Count**
Ocrevus (ocrelizumab) IV (300mg/30ml)	Information Unavailable
Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	Information Unavailable
Kesimpta (ofatumumab)	210
Briumvi (ublituximab)	Information Unavailable
Mavenclad (cladribine)	5<
Dimethyl Fumarate (Tecfidera)	0
Dimethyl Fumarate (generic)	311
Natalizumab (Tysabri)	Information Unavailable
Natalizumab (Tyruko)	0

Question:

3. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (November 2025 – April 2026)?

Answer:

There were 48 patients.

Question:

4. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?
   - Ocrevus (ocrelizumab) IV (300mg/30ml)
   - Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
   - Kesimpta (ofatumumab)
   - Briumvi (ublituximab)
   - Mavenclad (cladribine)
   - Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
   - Natalizumab (Tysabri and Tyruko)

Answer:

Medicine	Patients
Ocrevus (ocrelizumab) IV (300mg/30ml)	0
Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
Kesimpta (ofatumumab)	8
Briumvi (ublituximab)	12
Mavenclad (cladribine)	0
Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	8
Natalizumab (Tysabri and Tyruko)	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, \you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI/Pages/default.aspx

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive